Recent News

• 06.12.2026 - Certara Integrates D360™ with Secondary Intelligence™ Software to Enhance Predicting Drug Safety Risk
• 06.11.2026 - Certara Reappointed for a European Medicines Agency Contract, Expanding Opportunities to Shape the Future of Real-World Evidence for Regulatory Decision-Making
• 06.11.2026 - 2026 Simcyp Workshops
• 06.11.2026 - QSP Modeling for Parkinson’s Disease: Solving the Synthetic Control Challenge in Clinical Trials
• 06.10.2026 - Mechanistic MIDD: Achieving Regulatory Success Through Strong Scientific Foundations
• 06.10.2026 - Model Smarter, Not Harder: Introducing Model Designer
• 06.09.2026 - Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study
• 06.09.2026 - Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies
• 06.09.2026 - Beyond Compliance: What ICH M15 Means for the Future of Drug Development
• 06.09.2026 - How interactive value communication tools strengthen the value proposition in healthcare

Recent Filings

• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2026 - 8-K Current report
• 05.15.2026 - 4 Statement of changes in beneficial ownership of securities